BSD Medical is Now Pyrexar Medical

The ESHO 35 (European Society of Hyperthermic Oncology) just wrapped up in Cologne, Germany last week. Representing Pyrexar at the event was the team from Dr. Sennewald Medizintechnik. Dr. Sennewald is the primary sponsor of this year's event and has supported this event since its founding.

The event was held at the KOMED event center in the MediaPark in downtown Cologne. The conference included two days of lectures and presentations covering all aspects of thermal therapy advancements. It is often an opportunity for researchers to present status updates on ongoing projects.  Dr. Dario Rogriques, Assistant Professor of Radiation Oncology at the University of Maryland School of Medicine presented the details of an upcoming animal study for the Pyrexar Hal.o head applicator for the treatment of glioblastoma.

Dr. Rodriques's program objective is to evaluate numerically the feasibility of focused heating in the minipig brain using the noninvasive MR-compatible brain applicator (Hal.o) and assess the feasibility of partial brain heating to design blood perfusion measurement experiments to improve the accuracy of temperature simulations using large mammal data.  A full-scale prototype has been built and tested to verify heating performance.

The First Annual Department of Radiation Oncology Research Symposium was held at the University of Maryland's Medical School Teaching Facility. The symposium gives faculty, residents, and student researchers the opportunity to showcase their research projects.

Dario Rodrigues, Ph.D., Assistant Professor in the Radiation Oncology department, placed first place in the poster category.  His poster summarized the work he has been doing to verify the use of Pyrexar's Hal.o applicator, a Non-Invasive, Non-Ionizing Radiation approach to produce a focused heat zone in the brain.

It has been demonstrated in a study published in the International Journal of Radiation Biology & Physics (Sneed, 1998 Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme) that hyperthermia can boost the effectiveness of radiotherapy when treating glioblastoma.  Pyrexar Engineering has been working on an applicator to provide focused hyperthermia under MR guidance for several years.  Dr. Rodrigues is currently developing a study protocol to begin animal studies. 

Join us in recognizing Dr. Rodrigues for his accomplishments.

According to the Global Cancer Observatory, the top three cancer indications in China are lung cancer, liver cancer, and stomach cancer. Lung cancer is the most common type of cancer in China, accounting for approximately 25% of all cancer cases. Liver cancer is the second most common type of cancer, accounting for around 19% of cases, and stomach cancer is the third most common, accounting for about 8% of cases. These three types of cancer are a significant public health concern in China and are a major focus of cancer research and treatment in the country.

Recently, Ray Lauritzen, the VP of Service at Pyrexar Medical, visited several hospitals in China to observe the use of the BSD-2000 hyperthermia system. This system uses heat to target cancer cells and has been shown to be an effective complementary therapy to traditional treatments. Its adoption in China is growing and for good reason.

In addition to the use of hyperthermia, Traditional Chinese Medicine (TCM) is also an important aspect of cancer treatment in the country. It is based on the idea that the body is a complex system of interconnected parts that work together to maintain health and well-being.

Traditional therapies such as acupuncture and herbal remedies are often used with modern Western treatments to help patients manage their symptoms and improve their quality of life. With modern hospitals and skilled medical professionals, China is well-positioned to provide comprehensive and effective cancer care to its citizens.

A special thank you to the team at Dailan Orientech Co.,Ltd. for hosting the tours and continuing to expand hyperthermia throughout the region.

Great news! We are excited to share that our CE mark for Pyrexar Medical's product line of RF Hyperthermia Systems, including the BSD-500 Superficial/Interstitial Hyperthermia System, the BSD-2000, BSD-2000 3D and BSD-2000 3D/MR Deep Regional Hyperthermia System, has been renewed.

Although this may not come as a surprise to some, we wanted to highlight that the process of receiving this certification has become much more rigorous under the new EU MDR (European Union Medical Device Regulation 2017/745) framework. This was necessary to ensure a more robust, transparent, sustainable, and predictable regulatory framework and improve the overall level of health and safety of medical devices, while still supporting innovation in the industry.

We understand that this has resulted in many medical device manufacturers withdrawing products from the European Union, but at Pyrexar Medical, we believe that the benefits of hyperthermia are important for patients worldwide. We are committed to continuing to bring these benefits to the European Union and all parts of the world, and the rigorous process of receiving the CE marking is an important step in that direction.

Although the process was expensive and time-consuming, it was well worth it, and we are excited to continue to innovate and improve healthcare through our hyperthermia systems. Thank you for your support and trust in Pyrexar Medical.